Selected article for: "efficient vaccine and SARS vaccine development"
Author: Shirvani, Edris; Samal, Siba K.
Title: Newcastle Disease Virus as a Vaccine Vector for SARS-CoV-2
  • Cord-id: 6hteott0
  • Document date: 2020_7_29
    • ID: 6hteott0
    Snippet: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in more than 16 million infections and more than 600,000 deaths worldwide. There is an urgent need to develop a safe and effective vaccine against SARS-CoV-2. Currently, several strategies are being pursued to develop a safe and effective SARS-CoV-2 vaccine. However, each vaccine strategy has distinct advantages and disadvantages. Therefore, it is important to evaluate multiple vaccine platforms to select
    Document: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in more than 16 million infections and more than 600,000 deaths worldwide. There is an urgent need to develop a safe and effective vaccine against SARS-CoV-2. Currently, several strategies are being pursued to develop a safe and effective SARS-CoV-2 vaccine. However, each vaccine strategy has distinct advantages and disadvantages. Therefore, it is important to evaluate multiple vaccine platforms to select the most efficient vaccine platform for SARS-CoV-2. In this regard, Newcastle disease virus (NDV), an avian virus, has several well-suited properties for development of a vector vaccine against SARS-CoV-2. Here, we elaborate on the idea of considering NDV as a vaccine vector for SARS-CoV-2.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and adaptive innate immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and additional protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute respiratory syndrome and live sars handling: 1
    • acute respiratory syndrome and live vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and live viral vaccine: 1, 2, 3
    • acute respiratory syndrome and live viral vector vaccine: 1, 2, 3
    • acute respiratory syndrome and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and live virus vaccine: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and local immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and local systemic immunity: 1, 2, 3
    • adaptive innate and additional protein: 1, 2
    • adaptive innate and live vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • adaptive innate and live viral vaccine: 1, 2
    • adaptive innate and live viral vector vaccine: 1
    • adaptive innate and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • adaptive innate and live virus vaccine: 1, 2, 3, 4, 5, 6
    • adaptive innate and local immunity: 1, 2, 3, 4, 5
    • adaptive innate immunity and live virus vaccine: 1, 2
    • adaptive innate immunity and local immunity: 1, 2